The efficacy hurdle was cleared, but the biggest directional surprise is limited. The positive ACACIA-HCM topline result was already public before this filing, so the August 28 release mainly supplies the full dataset rather than announcing an unexpected trial outcome. The filing confirms that both prespecified primary endpoints were statistically significant at Week 36. 〔0〕
| Measure | Aficamten | Placebo | Difference / result |
|---|---|---|---|
| KCCQ-CSS change at Week 36 | 11.4 | 8.4 | +3.0 points; p=0.021 (Dual Primary Endpoint Results) |
| pVO₂ change at Week 36, ml/kg/min | 0.64 | -0.03 | +0.67; p=0.003 (Dual Primary Endpoint Results) |
| Improved by at least one NYHA class | 41.9% | 27.8% | +14.1 percentage points; p<0.001 (Secondary Endpoints) |
| Clinical response in at least three of five domains | 53% | 13% | +40 percentage points; p<0.001 (Global Efficacy Analysis) |
| LVEF below 50% | 10.5% | 0.8% | Safety imbalance (ACACIA-HCM: Safety) |
| Serious adverse events | 20.2% | 14.7% | Higher with aficamten (ACACIA-HCM: Safety) |
The full results strengthen the case that aficamten works across symptoms and function. The treatment effect was consistent across prespecified subgroups, while NYHA class, exercise-testing measures and NT-proBNP also improved significantly. 〔1〕 The 53% versus 13% global-response result is particularly supportive because it indicates improvement across multiple dimensions of disease burden, not just one statistical endpoint.
Safety prevents this from being a clean efficacy-only win. LVEF fell below 50% in 27 aficamten patients versus two on placebo, and serious adverse events were also more frequent. 〔2〕 The cardiovascular-event endpoint itself was not statistically improved, with events in 8.5% of aficamten patients versus 7.7% on placebo, and the left-atrial-volume endpoint also missed significance. Those findings do not invalidate the trial, but they preserve regulatory, monitoring and commercial friction around a drug already carrying heart-failure warnings and REMS requirements.
The net read is confirmation at the expected clinical bar, not a wholly new re-rating event. The filing supports a broader nHCM label and keeps the company on track to submit a supplemental FDA application in the fourth quarter of 2026. 〔3〕 Against the already-public positive topline, the full release adds credibility and useful detail, but the safety signal means the overall information is best characterized as mixed rather than decisively above expectations.
Read the original 8-K on SEC EDGAR ↗